SEC Filing Summary: Athira Pharma, Inc. (ATHA)
Business Context and Reporting Period
This Form 8-K was filed by Athira Pharma, Inc. on November 7, 2024. The filing serves to report the Company's financial results for the quarter ended September 30, 2024, as detailed in a press release furnished as Exhibit 99.1. The registrant is an emerging growth company incorporated in Delaware.
Note: The request metadata referenced "Leonabio, Inc.", but the provided filing text explicitly identifies the registrant as "Athira Pharma, Inc."
Key Financial Metrics
The provided text is a cover sheet and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the referenced press release (Exhibit 99.1), which is not included in the input text.
Material Changes
The filing does not provide specific details on material changes versus the prior comparable period. It only confirms that results for the quarter ended September 30, 2024, have been issued.
Guidance, Outlook, and Risks
- Disclosure Channels: The Company utilizes its website, investor relations portal, and social media platforms (X, LinkedIn, Instagram, Facebook) to disseminate material information.
- Regulation FD: The filing includes a standard Regulation FD disclosure statement, noting that information released through these channels may be deemed material.
- Outlook/Guidance: No specific forward-looking guidance or management commentary is present in the text of this 8-K form itself.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (the press release dated November 7, 2024), as they are not listed in this summary document.
- Confirm the Company's status as an Emerging Growth Company and its implications for financial reporting standards.
- Review the Company's social media channels and investor relations website for any additional material updates referenced in Item 7.01.
- Ensure the correct entity name is used in analysis (Athira Pharma, Inc., not Leonabio, Inc.).